Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This treatment protocol will enable therapeutic use of Anascorp in the management of systemic manifestations of scorpion sting envenomation, in patients for whom antivenom would otherwise be unavailable. The working hypotheses are as follows:

1. The investigational antivenom is safe as treatment of scorpion sting envenomation.

2. The investigational antivenom is effective as treatment of scorpion sting envenomation.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Bioclon S.A. de C.V.
• Collaborator: University of Arizona
• Treatments: Antivenins

Criteria

Inclusion Criteria:

• Males and females of any age presenting for emergency treatment with clinically important systemic signs of scorpion sting envenomation

• Signed written Informed Consent by patient or legal guardian

Exclusion Criteria:

• Allergy to horse serum